Critical Survey: Q32 Bio (NASDAQ:QTTB) and Travere Therapeutics (NASDAQ:TVTX)

Travere Therapeutics (NASDAQ:TVTX) and Q32 Bio (NASDAQ:QTTB) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Travere Therapeutics and Q32 Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Q32 Bio	N/A	50.17%	29.49%

Analyst Recommendations

This is a summary of current ratings and target prices for Travere Therapeutics and Q32 Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	2	0	10	0	2.67
Q32 Bio	0	2	6	1	2.89

Travere Therapeutics presently has a consensus target price of $69.50, suggesting a potential upside of 37.92%. Q32 Bio has a consensus target price of $32.17, suggesting a potential upside of 261.02%. Given Q32 Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Travere Therapeutics.

Earnings & Valuation

This table compares Travere Therapeutics and Q32 Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73 million	9.68	-$25.55 million	($0.46)	-109.54
Q32 Bio	$53.74 million	4.94	$29.82 million	$3.00	2.97

Q32 Bio has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

Insider and Institutional Ownership

31.3% of Q32 Bio shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Q32 Bio beats Travere Therapeutics on 11 of the 15 factors compared between the two stocks.

About Travere Therapeutics

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.